Trial Profile
A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Painful Diabetic Neuropathy (EMPADINE)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Olodanrigan (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms EMPADINE
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Oct 2021 Results of safety and efficacy data from two phase II studies (EMPHENE and EMPADINE) published in the Pain.
- 20 May 2020 Status changed from completed to discontinued(Study was terminated due to animal toxicity data).
- 04 Feb 2020 Status changed to completed.